Postexposure Zidovudine May Reduce HIV Risk

Aromatase inhibitors may reduce endometrial cancer risk.

Use of aromatase inhibitors, which are known to reduce endogenous oestrogen levels, as adjuvant therapy had a lower risk of endometrial cancer, compared with that of patients who were treated with tamoxifen, results of a new study show. In this study, Rowan Chleblowski and colleagues (Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Los Angeles, CA, USA) examined the rec...

Finasteride and dutasteride may reduce melanoma risk.

Malignant melanoma is an androgen-dependent tumor. Androgen blockade enhances response to the melanoma vaccine. In their study, Zhang et al reported that a history of teenage acne in women may be a novel risk factor for melanoma independent of other risk factors. Acne in women is related to androgens and can be treated with finasteride. Both finasteride and dutasteride prevent the conversion of...

HIV postexposure prophylaxis: new recommendations.

A lthough the average risk of acquiring HIV infection after percutaneous exposure to HIV-infected blood is only 0.3%, health care workers welcomed the news that postexposure prophylaxis with zidovudine (AZT) can reduce this risk by as much as 79.0%. Recommendations from the US Centers for Disease Control and Prevention (CDC) have been revised to take into account the potential for greater benef...

HIV postexposure prophylaxis for Special Forces soldiers.

Exposure to human immunodeficiency virus (HIV) is a recognized occupational hazard to healthcare personnel. The virus also presents an operational hazard to deployed Special Operations Forces (SOF) personnel. Management guidelines for work related exposure to HIV mainly deal with healthcare workers in a first world hospital environment. Formal guidelines for postexposure prophylaxis (PEP) regar...

German-Austrian recommendations for HIV postexposure prophylaxis.